RARE News and Press, Ultragenyx Pharmaceutical Inc. From 07/18/22

Ultragenyx Pharmaceutical ( NASDAQ: RARE ) on Monday said it had exercised its option to acquire GeneTx Biotherapeutics for a $75M upfront payment following promising interim data from a phase 1/2 study of the privately-held biotech company's investigational drug GTX-102. ...

Doses up to 10 mg show good tolerability and meaningful clinical activity in multiple domains U.K. and Canadian health authorities approved escalation to higher doses Ultragenyx exercises option to acquire GeneTx for $75 million upfront payment Conference call to...

Ultragenyx Pharmaceutical ( NASDAQ: RARE ) said it sold 30% of its royalty interest from Kyowa Kirin ( OTCPK:KYKOF ) on their drug  Crysvita in the U.S. and Canada to Canadian public pension fund OMERS for $500M. OMERS' right to receive royalty ...

Strengthens balance sheet with non-dilutive capital at an attractive cost Competitive process results in the sale of 30% of the Ultragenyx royalty interest, subject to a 1.45x cap Proceeds to fund planned clinical and commercial activities NOVATO, Calif., July 14, ...

Ultragenyx is a rare disease drug developer. Its execution, so far, has been near perfect. The company has a long pipeline and oodles of cash. For further details see: Ultragenyx: Convincing Investment Thesis For This Orphan Drug Developer

Update 7:55am: Adds Times report on advisers for a potential deal. The ADRs of Mereo BioPharma (MREO) jumped ~15% in the pre-market Friday after The Times reported that the Anglo-Dutch pharma giant AstraZeneca (NASDAQ:AZN) is considering a bid for the U.K.-based biotech. In 201...

The ADRs of Mereo BioPharma (MREO) jumped ~15% in the pre-market Monday after The Times reported that Anglo Dutch pharma giant AstraZeneca (NASDAQ:AZN) is considering a bid for the U.K.-based biotech. AstraZeneca (AZN) already has a partnership with Mereo (MREO). According to the re...

Time to put money to work. Merger arb spreads are wide. Here’s what you can buy today. For further details see: Golden Age Of Merger Arb: Anaplan

NOVATO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D....

NOVATO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D....